Parenteral iron nephrotoxicity: Potential mechanisms and consequences

Kidney International

Volumn 66, Issue 1, 2004, Pages 144-156

  Zager, Richard A ^a,b   Johnson, Ali C M ^a   Hanson, Sherry Y ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Heme oxygenase 1; Iron dextran; Iron gluconate; Iron sucrose; Oxidant stress

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME; DEXTRAN; FERRITIN; FERROUS GLUCONATE; HEME OXYGENASE 1; IRON; IRON COMPLEX; LACTATE DEHYDROGENASE; MALONALDEHYDE; MESSENGER RNA; OLIGOSACCHARIDE; SUCROSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CELL DAMAGE; CELL INTERACTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; ELECTRON MICROSCOPY; ENZYME RELEASE; EXPOSURE; HEART; HOMEOSTASIS; IN VIVO STUDY; INJECTION; IRON OVERLOAD; IRON TRANSPORT; KIDNEY; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; LIPID PEROXIDATION; MOLECULAR MECHANICS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY TESTING;

EID: 3042769328     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00716.x     Document Type: Article

References (48)

1. NISSENSON AR, STROBOS J: Iron deficiency in patients with renal failure. Kidney Int 59(Suppl 69):S18-S21, 1999
2. NATIONAL KIDNEY FOUNDATION: DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kid Dis 37(Suppl 1):S182-S238, 2001
3. MACDOUGALL IC, HORL WH, JACOBS C, et al: European Best Practice Guidelines 6-8: Assessing and optimizing iron stores. Nephrol Dial Transplant 15(Suppl 4):20-32, 2000
4. FAICH G, STROBOS J: Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kid Dis 37:743-749, 1999
5. ZAGER RA, JOHNSON ACM, HANSON SY, WASSE H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103, 2002
6. SALAHUDEEN AK, OLIVER B, BOWER JD, OBERTS LJ: Increase in plasma esterified F-2 isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525-1531, 2001
7. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 8:475-486, 1997
8. LIM PS, WEI YH, YU YL, KHO B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dialysis Transplant 14:2680-2687, 1999
9. CAVDAR C, TEMIZ A, YENICERIOGLU Y, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 37:77-82, 2000
10. ROOYAKKERS TM, STROES ES, KOOISTRA MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(Suppl 1):9-16, 2002
11. SENGOELGE G, KLETZMAYR J, FERRARA I, et al: Impairment of trans-endothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14:2639-2644, 2002
12. DRUEKE T, WITKO-SARSAT V, MASSY Z, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
13. BECKER BN, HIMMELFARB J, HENRICH WL, HAKIM RM: Re-assessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
14. GACKOWSKI D, KRUSZEWSKI M, JAWIEN A, et al. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. Free Radical Biol Med 31:542-547, 2001
15. PONRAJ D, MAKJANIC J, THONG PS, et al. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 459:218-222, 1999
16. DAUGHERTY A: Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipid 8:11-12, 1997
17. CORTI MC, GAZIANO M, HENNEKENS CH: Iron status and risk of cardiovascular disease. Ann Epidemiol 7:62-68, 1997
18. SPITTLE MA, HOENICH NA, HANDELMAN GJ, et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
19. RAHMAN I, MACNEE W: Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Rad Biol Med 28:1405-1420, 2000
20. HADDAD JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cellular Signalling 14:879-897, 2002
21. XIONG S, SHE H, TAKEUCHI H, et al. Signaling role of intracellular iron in NF-kappa B activation. J Biol Chem 278:17646-17654, 2003
22. SUKAMOTO H: Iron regulation of hepatic macrophage TNF alpha expression. Free Radical Biol Med 32:309-313, 2002
23. OWEN WF, LOWRIE EG: C reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
24. ZOCCALI C, BENEDETTO FA, MALLAMACI F, et al: Inflammation is associated with carotid atherosclerosis in hemodialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18:1207-1213, 2000
25. ISEKI K, TOZAWA M, YOSHI S, FUKIYAMA K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956-1960, 1999
26. NATH KA, VERCELLOTTI GM, GRANDE JP, et al. Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1. Kidney Int 59:106-117, 2001
27. FERNANDEZ-REAL JM, LOPEZ-BERMEJO A, RICART W: Cross-talk between iron metabolism and diabetes. Diabetes 51:2348-2354, 2002
28. SHAH SV: The role of reactive oxygen metabolites in glomerular disease. Ann Rev Physiol 57:245-262, 1995
29. BALIGA R, UEDA N, WALKER PD, SHAH SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 29:465-477, 1997
30. ZAGER RA, BURKHART KM, CONRAD DS, GMUR DJ: Iron, heme oxygenase, and glutathione effects on myohemoglobinuric proximal tubular injury. Kidney Int 48:1624-1634, 1995
31. ZAGER RA, JOHNSON ACM, HANSON SY: Proximal tubular cytochrome c efflux: Determinants and a potential marker of mitochondrial injury. Kidney Int (in press)
32. ZAGER RA: Hyperthermia: Effects on renal ischemic/reperfusion injury in the rat. Lab Invest 63:360-369, 1990
33. ZAGER RA, SCHIMPF BA, GMUR DJ: Physiologic pH: Effect on posthypoxic proximal tubular injury. Circ Res 72:837-846, 1993
34. GAMELIN LM, ZAGER RA: Evidence against oxidant injury as a critical mediator of post ischemic acute renal failure. Am J Physiol 255:F450-F460, 1988
35. JOHNSON AC, YABU JM, HANSON S, et al. Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. Am J Pathol 162:283-291, 2003
36. NATH KA, BALLA G, VERCELLOTTI GM, et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90:267-270, 1992
37. CARRAWAY MS, GHIO AJ, TAYLOR JL, PIANTADOSE CA: Induction of ferritin and heme oxygenase-1 by endotoxin in the lung. Am J Physiol 275:L583-L592, 1998
38. ZAGER RA, SHAH VO, SHAH HV, et al. The mevalonate pathway during acute tubular injury: Selected determinants and consequences. Am J Pathol 161:681-692, 2002
39. CHEN Z, FRIEDRICH GA, SORIANO P: Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Develop 8:2293-2301, 1994
40. RYAN MJ, JOHNSON G, KIRK J, et al. HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45:48-51, 1994
41. MANCINI M, ANDERSON BO, CALDWELL E, et al. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 138:449-469, 1997
42. ZAGER RA: Heme protein-induced tubular cytoresistance: Expression at the plasma membrane level. Kidney Int 47:1336-1345, 1995
43. ZAGER RA, BURKHART KM, JOHNSON ACM, SACKS B: Increased proximal tubular cholesterol content: Implications for cell injury and "acquired cytoresistance." Kidney Int 56:1788-1797, 1999
44. HONDA N, HISHIDA A, IKUMA K, YONEMURA K: Acquired resistance to acute renal failure. Kidney Int 31:1233-1238, 1987
45. 2 deprivation, possibly by inducing uremia. Kidney Int 47:1760-1768, 1994
46. VAN WYCK D: Error, not iron, causes cytotoxicity. Am J Kidney Dis 40:1109-1110, 2002
47. ZAGER RA, SCHIMPF BA, GMUR DJ: Physiologic pH: Effect on posthypoxic proximal tubular injury. Circ Res 72:837-846, 1993
48. AGARWAL R, VASAVADA N, SACHS NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int (in press)